<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332254</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00014439</org_study_id>
    <secondary_id>7939-05-11</secondary_id>
    <nct_id>NCT00332254</nct_id>
  </id_info>
  <brief_title>Study to Prevent Cartilage Damage Following Acute Knee Injury.</brief_title>
  <official_title>IL-1ra for Prevention of Chondropathy Following Knee Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals who have had a severe knee injury have an increased risk of developing arthritis
      of the knee and at a much earlier age than would otherwise be expected. The swelling and
      inflammation that occur after injury are believed to be responsible for this cartilage
      damage. The cartilage (material that provides a cushion in the knee) is the primary
      protection from what is called degenerative arthritis or osteoarthritis. We hope to reduce
      this swelling and prevent the damage to cartilage that occurs after injury by injecting a
      medication that blocks one of the proteins responsible for inflammation and cartilage
      breakdown. This protein is called interleukin-1 and can be inhibited by an interleukin-1
      receptor antagonist called anakinra. Anakinra will be injected directly into the injured knee
      and response to the injection will be measured by symptoms and analysis of cartilage
      breakdown in the knee fluid and blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis is highly prevalent with significant impact on health care utilization and
      personal suffering. Injury predisposes to OA even after surgical correction (1, 2).
      Definitive therapy for established OA is lacking and current treatments are increasingly
      questioned with regard to long-term safety. Interleukin-1 is instrumental in OA pathogenesis
      (3-5). Recent studies by Chevalier demonstrated that intra-articular use of IL-1ra was safe
      in patients with established OA (6). We hope to show that IL-1ra will provide symptomatic
      benefit after knee injury as well as decreasing cartilage breakdown.

      The trial will consist of trial administering 150mg of Anakinra, or placebo, within 30 days
      of an acute knee injury that requires surgical repair. We hypothesize that higher IL-1 in
      synovial fluid after injury will predict greater symptomatic response to IL-1ra. Outcome
      measures will be functional and pain assessments at regular intervals before and after
      surgery (7, 8). Cartilage catabolism will be assessed with two primary measures. First we
      will assess degree of chondropathy via direct cartilage visualization and scoring at the time
      of arthroscopic repair (9). Secondly, the impact of IL-1ra on the inflammatory milieu will be
      determined through analysis of serum and synovial fluid cytokine levels and cartilage
      biomarkers at enrollment and again at the time of surgical repair.

      The impetus for this study is based on previous work done in animal models of OA, showing
      prevention of cartilage damage following surgically induced ACL injury (10-12). We believe
      that intra-articular delivery of anakinra within a short time following knee injury will
      improve patient function and pain reporting and will also prevent chondropathy that results
      from injury.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain</measure>
    <time_frame>4 and 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>chondropathy score</measure>
    <time_frame>30-60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Knee Injury</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular IL-1Ra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-articular saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>150 mg IL1Ra ia x1 vs saline ia x1</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Onset of injury less than 4 weeks prior to evaluation

          -  Severe knee injury that requires surgery, including anterior cruciate ligament tear,
             meniscus tear and chondral injury

          -  BMI less than 30

          -  Age 18-30

          -  Women will have serum pregnancy testing (bHCG) at time of entry and on follow-up
             evaluation and must agree to use an approved form of contraception during the study
             period.

        Exclusion Criteria:

          -  Prior signal joint injury requiring medical evaluation

          -  History of arthritis or rheumatic disease

          -  History of intra-articular corticosteroid in index joint

          -  Septic joint

          -  Evidence of chronic joint disease by plain radiograph

          -  Fracture or multiple ligament tear

          -  Pregnancy or lactation

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia B Kraus, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Sports Medicine Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gelber AC, Hochberg MC, Mead LA, Wang NY, Wigley FM, Klag MJ. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med. 2000 Sep 5;133(5):321-8.</citation>
    <PMID>10979876</PMID>
  </reference>
  <reference>
    <citation>Roos EM. Joint injury causes knee osteoarthritis in young adults. Curr Opin Rheumatol. 2005 Mar;17(2):195-200. Review.</citation>
    <PMID>15711235</PMID>
  </reference>
  <reference>
    <citation>Pelletier JP, DiBattista JA, Roughley P, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am. 1993 Aug;19(3):545-68. Review.</citation>
    <PMID>8210574</PMID>
  </reference>
  <reference>
    <citation>Pelletier JP, McCollum R, Cloutier JM, Martel-Pelletier J. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol Suppl. 1995 Feb;43:109-14.</citation>
    <PMID>7752112</PMID>
  </reference>
  <reference>
    <citation>Lotz M. Cytokines in cartilage injury and repair. Clin Orthop Relat Res. 2001 Oct;(391 Suppl):S108-15. Review.</citation>
    <PMID>11603695</PMID>
  </reference>
  <reference>
    <citation>Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol. 2005 Jul;32(7):1317-23.</citation>
    <PMID>15996071</PMID>
  </reference>
  <reference>
    <citation>Paxton EW, Fithian DC, Stone ML, Silva P. The reliability and validity of knee-specific and general health instruments in assessing acute patellar dislocation outcomes. Am J Sports Med. 2003 Jul-Aug;31(4):487-92.</citation>
    <PMID>12860533</PMID>
  </reference>
  <reference>
    <citation>Irrgang JJ, Anderson AF. Development and validation of health-related quality of life measures for the knee. Clin Orthop Relat Res. 2002 Sep;(402):95-109. Review.</citation>
    <PMID>12218475</PMID>
  </reference>
  <reference>
    <citation>Ayral X, Dougados M, Listrat V, Bonvarlet JP, Simonnet J, Poiraudeau S, Amor B. Chondroscopy: a new method for scoring chondropathy. Semin Arthritis Rheum. 1993 Apr;22(5):289-97.</citation>
    <PMID>8511593</PMID>
  </reference>
  <reference>
    <citation>Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 1997 Jun;40(6):1012-9.</citation>
    <PMID>9182910</PMID>
  </reference>
  <reference>
    <citation>Fernandes J, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, Sheppard M, Krishnan BR, Pelletier JP. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol. 1999 Apr;154(4):1159-69.</citation>
    <PMID>10233854</PMID>
  </reference>
  <reference>
    <citation>Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, Pelletier JP. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum. 1996 Sep;39(9):1535-44.</citation>
    <PMID>8814066</PMID>
  </reference>
  <reference>
    <citation>Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and Osteoarthritis Outcome Score (KOOS)--development of a self-administered outcome measure. J Orthop Sports Phys Ther. 1998 Aug;28(2):88-96.</citation>
    <PMID>9699158</PMID>
  </reference>
  <reference>
    <citation>Kessler S, Lang S, Puhl W, St√∂ve J. [The Knee Injury and Osteoarthritis Outcome Score--a multifunctional questionnaire to measure outcome in knee arthroplasty]. Z Orthop Ihre Grenzgeb. 2003 May-Jun;141(3):277-82. German.</citation>
    <PMID>12822074</PMID>
  </reference>
  <reference>
    <citation>Marks PH, Donaldson ML. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy. 2005 Nov;21(11):1342-7.</citation>
    <PMID>16325085</PMID>
  </reference>
  <reference>
    <citation>Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods. 2004 Nov;294(1-2):145-53.</citation>
    <PMID>15637808</PMID>
  </reference>
  <reference>
    <citation>Matyas JR, Atley L, Ionescu M, Eyre DR, Poole AR. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum. 2004 Feb;50(2):543-52.</citation>
    <PMID>14872497</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2006</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anterior cruciate ligament tear</keyword>
  <keyword>Meniscus tear</keyword>
  <keyword>Chondral injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Knee Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

